Company intelligence / Profile preview
Genetic Leap
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Genetic Leap has advanced a pipeline of AI-driven RNA-targeted therapeutics. It recently received FDA IND clearance for a first-in-class oral IL-2 modulator, marking its lead candidate's advancement into the clinic. The company has entered a major collaboration with Eli Lilly to accelerate development of RNA-targeting oligonucleotide medicines using its proprietary AI platform.[3][4][5]
- Modalities
- OligonucleotideSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Eli Lilly
Beyond the preview
Go deeper on Genetic Leap.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genetic Leap.